# RNA Nanoparticles-Displaying Exosomes to enhance targeted siRNA delivery for Prostate Cancer treatment.

> **NIH NIH R43** · EXONANORNA, LLC · 2022 · $294,528

## Abstract

PROJECT SUMMARY
Prostate Cancer is the most common type of cancer diagnosed in the male population and the sixth cause
of death every year. While different therapeutic strategies are available for the clinical management of the
disease (surgery, radiation therapy, chemotherapy, hormonal therapy) research is shifting to innovative
approaches based on the delivery of RNA interfering agents, including small interfering RNA (siRNA).
Despite their efficacy in promoting tumor suppression, siRNA-based strategies are negatively affected by
poor delivery of siRNA, short half-life in vivo, and alteration of the immune response, which hinder their
translation into clinical practice. Exosomes have been proposed as delivery nanoparticles thanks to their
natural involvement in intercellular transport of protein and nucleic acids. However, exosomes suffer from
technical limitations (low targeting efficiency, poor biodistribution, endosome trapping). ExonanoRNA
proposes a novel approach based on RNA Nanotechnology to generate RNA Nanoparticles-Displaying
Exosomes for the targeted delivery of siRNA in prostate cancer cells. The use of RNA nanoparticles
associated with exosomes allows superior cell targeting and efficient delivery of siRNA. Exosomes are
engineered to display a favorable pharmacokinetic profile and low immunogenicity and to avoid endosome
trapping. The company has preliminary validated the use of nanoparticle orientation to control RNA loading
and ligand display on exosomes in a proof-of-concept study that supports the use of RNA nanoparticles-
loaded Exosomes to target prostate cancer. In this SBIR Phase I project, ExonanoRNA will generate lead
candidates with high level of stability, production efficiency, therapeutic efficacy, and safety suitable for
clinical testing. This goal will be achieved through two aims. Aim 1) selection of the most appropriate
targeting ligand to ensure the maximum specificity to prostate cells and identification of the optimal number
of RNA NPs associated to the EVs to achieve the most efficient targeting efficiency. Aim 2) The best
candidate will be tested in vitro on human prostate adenocarcinoma (LNCaP+) cells, and in vivo on
xenografts mice to investigate efficacy, and safety. The proposed activities will lead to a Phase II project
where ExonanoRNA foresees the scale up of production of the validated candidate and perform IND-
enabling studies in small and large animals (rat, beagle dog).

## Key facts

- **NIH application ID:** 10483260
- **Project number:** 1R43CA268253-01A1
- **Recipient organization:** EXONANORNA, LLC
- **Principal Investigator:** Shanqing Gu
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $294,528
- **Award type:** 1
- **Project period:** 2022-09-01 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10483260

## Citation

> US National Institutes of Health, RePORTER application 10483260, RNA Nanoparticles-Displaying Exosomes to enhance targeted siRNA delivery for Prostate Cancer treatment. (1R43CA268253-01A1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10483260. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*